Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1997
Business Overview: Aastrom is a development-stage biotechnology company focused on proprietary process technologies and devices for cell therapy, specifically stem cell and gene therapy. Its lead product, the Aastrom Cell Production System (CPS), is designed to enable the ex vivo production of human stem cells as an alternative to invasive bone marrow harvests. The company has no commercial product sales and relies on grants, research agreements, and equity financing.
Key Financial Metrics (Year Ended June 30, 1997)
| Metric | Value |
|---|---|
| Total Revenues | $378,000 |
| Net Loss | $(14,288,000) |
| Net Loss Per Share | $(1.26) |
| Research & Development Expenses | $13,357,000 |
| General & Administrative Expenses | $1,953,000 |
| Cash, Cash Equivalents & Short-Term Investments | $17,007,000 |
| Working Capital | $15,600,000 |
| Total Assets | $18,410,000 |
| Accumulated Deficit | $(41,313,000) |
| Long-Term Capital Lease Obligations | $65,000 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased significantly to $378,000 in 1997 from $1,609,000 in 1996. This was primarily due to the conclusion of a research collaboration with Rhone-Poulenc Rorer, Inc. (RPR) in September 1996, which had accounted for 83% of research agreement revenues in the prior year.
- Increased Losses: Net loss widened to $14.3 million in 1997 from $9.9 million in 1996, driven by a 32% increase in R&D expenses to $13.4 million. This increase included a $1 million license fee payment to Immunex Corporation.
- Liquidity Improvement: Cash and short-term investments increased by $6.0 million to $17.0 million, largely funded by an Initial Public Offering (IPO) in February 1997 that generated net proceeds of approximately $19.9 million.
- Capital Structure: All outstanding preferred stock was converted to common stock following the IPO. The company now has 13,275,208 shares of common stock outstanding.
Guidance, Outlook, and Risks
- Outlook: Management does not anticipate profitability for at least the next several years. Future revenues are expected to come from grants, research agreements, and milestone payments until commercial products are approved.
- Clinical Development: The company is conducting pre-pivotal clinical trials for the Aastrom CPS in stem cell therapy. Pivotal trials are anticipated to begin no earlier than late 1997, pending successful pre-pivotal results and FDA clearance.
- Strategic Partnership: Aastrom has a distribution agreement with Cobe BCT, Inc. for the worldwide marketing of the Aastrom CPS for stem cell therapy. Cobe receives approximately 38% to 42% of net sales. Cobe holds the right to terminate the agreement if commercialization by December 31, 1998, is deemed unlikely.
- Capital Needs: The company expects to require substantial additional funding for clinical trials, regulatory approvals, and product development. There is no assurance that future financing will be available on acceptable terms.
- Key Risks:
- Regulatory Uncertainty: The FDA has not finalized regulations for ex vivo cell therapy products; the Aastrom CPS is currently regulated as a Class III medical device requiring a Pre-Market Approval (PMA).
- Manufacturing Dependence: The company relies entirely on third-party suppliers (e.g., SeaMED, Ethox, Immunex) for manufacturing components and critical cytokines.
- Patent Reliance: Success depends on licenses from the University of Michigan and Dr. J.G. Cremonese; termination of these licenses would be materially adverse.
Investor Verification Checklist
- Cash Runway: Verify if the $17 million cash balance is sufficient to fund operations through the completion of pivotal trials, given the $14.3 million annual burn rate.
- Cobe Relationship: Confirm the status of the Cobe distribution agreement and the likelihood of Cobe exercising its termination rights if commercialization milestones are not met by 1998.
- Immunex Supply: Assess the risk associated with the $1 million annual renewal fee and the sole-source dependency on Immunex for critical cytokines.
- Clinical Trial Progress: Monitor the results of the ongoing pre-pivotal trials at four U.S. sites to determine if they support the initiation of pivotal trials in late 1997.
- Revenue Concentration: Note the high volatility in revenue streams due to the loss of the RPR collaboration and the lack of recurring commercial revenue.